AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06282523 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HMP app
Description: The HMP app is a meditation-based smartphone app designed to promote and protect psychological well-being through sustainable skills training. The program is grounded in constituents of psychological well-being identified in empirical literature. HMP provides core content, with instruction administered through a curriculum of guided practices. HMP has guided audio practices that address 4 constituents of well-being: awareness, connection, insight, and purpose.
Study NCT06282523 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HMRP web app
Description: The HMRP web app is a meditation-based web-based app designed to promote and protect psychological well-being through sustainable skills training. The program is grounded in constituents of psychological well-being identified in empirical literature. HMRP provides core content, with instruction administered through a curriculum of guided practices. HMRP has guided audio practices that address 4 constituents of well-being: awareness, connection, insight, and purpose.
Study NCT05434949 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test
Description: Three blood samples to be taken at 08.00, 10.00 and 12.00 on day 1 of the study.~The following day, after an overnight fast, a blood sample will be taken at 8.00, followed by a standardized breakfast provided by the study team at 8.30, and then two further blood samples at 10.00 and 12.00.
Study NCT05434949 — intervention group
Intervention type: OTHER
Intervention: Analyses of samples
Description: C4 will be measured in surplus serum from 30 adult lipid patients before starting on lipid-lowering therapy (either statin of PCSK9 therapy) and then again 3 months after starting on therapy. Blood samples will be collected as part of routine lipid management, no additional samples are required.
Study NCT06189508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NXT007
Description: In all groups, the NXT007 single dose administration will occur in the morning of Day 1 under fasted conditions. Study treatment will occur via the route of administration and at the site of injection specified for each group.
Study NCT05636995 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Aldosterone/Renin Ratio
Description: Blood sample collected to measure the aldosterone/renin ratio for the primary hyperaldosteronism screening.
Study NCT05088213 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: suction mini percutaneous nephrolithotomy
Description: 18Fr suction sheath (Weili, China) was inserted, and 12Fr mini-nephroscope was used, kidney stones was fragmented by pneumatic lithotriptor (LithoClast Master, Switzerland) or Ho:YAG laser（0.8-1.0W\*20-30Hz）, and stone fragments was sucked out with the suction sheath.
Study NCT05088213 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: standard percutaneous nephrolithotomy
Description: 24-30Fr sheath was inserted, and 20Fr nephroscope (Richard Wolf, Germany) was used, kidney stones was disintegrated and sucked out by ultrasonic-lithotripter (LithoClast Master, EMS, Switzerland or ShockPluse-SE, Olympus).
Study NCT04440592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-7117
Description: MT-7117
Study NCT04440592 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06197893 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: gingival unit graft+modified sling suture technique
Description: The GUG was obtained from the maxillary premolar area. A sulcular incision including the marginal gingival tissue, and two vertical incisions, including the distal and mesial papillae, was made in the palatial parts of the premolars. Then, the incision lines were combined and a 1-1.5 mm thick graft of the desired dimensions was dissected. The dissected graft was fixed to the recipient site with 5/0 polypropylene suture using a modified sling suture technique. First, the needle was passed through the graft slightly apical to the mesial papilla on the buccal side and removed from the lingual aspect including lingual papilla. Subsequently, on the distal side, the needle was passed from the lingual side to the buccal side, and it was passed through the graft slightly apical to the distal papilla and removed from the lingual gingiva again. Then it was knotted on the buccal graft by returning to the buccal starting point on the mesial side.
Study NCT06197893 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gingival unit graft and conventional suture technique
Description: The GUG was obtained from the maxillary premolar area. The dissected graft was fixed to the recipient site with 5/0 polypropylene suture using conventional suture technique. Conventional suture technique includes a horizontal matrix suture and 2 simple sutures. First the coronal part of the dissected graft was fixed to the recipient bed with a horizontal matrix suture, then with 2 simple sutures along the vertical incision line from mesial and distal sides with 5/0 polypropylene suture.
Study NCT06197893 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional graft and modified sling suture technique
Description: Conventional graft dimensions were determined with aluminum foil and the foil was placed in the palatinal region at the level of the maxillary premolars, at least 2 mm away from the free gingival margin of the adjacent teeth. The exterier edges of the foil were drawn with a scalpel and the 1-1.5 mm thick graft was dissected from the donor site. The dissected graft was fixed to the recipient site with 5/0 polypropylene suture using a modified sling suture technique.
Study NCT06197893 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional graft and conventional suture technique
Description: Conventional graft obtained from the palatinal region at the level of the maxillary premolars, at least 2 mm away from the free gingival margin of the adjacent teeth. The dissected graft was fixed to the recipient site with 5/0 polypropylene suture using conventional suture technique.
Study NCT05038592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV
Study NCT05038592 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tagraxofusp-erzs
Description: Given IV
Study NCT05473676 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic Training Period
Description: Participants will engage in robot assisted gait training on at least 5 days/week for at least 30 minutes each day, for a total period of 12 weeks.
Study NCT05306418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mim8
Description: For treatment part 1, all participants will start on once-weekly treatment and continue on this regimen until week 26. For treatment part 2, starting at week 26, all participants will be offered the choice to remain on once-weekly or switch to once-monthly dosing.~Mim8 will be injected with a thin needle into the skin
Study NCT06579378 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VSail 3D
Description: The CEREBRUM software with virtual sailing scenarios is made up of exercises of variable difficulty, designed to train different cognitive functions, in particular attention, memory, learning, cognitive estimates, working memory, executive functions, motor abilities and language. The different degrees of difficulty are designed to adapt to the user's functional diagnosis. The operator who conducts the intervention must adapt the difficulty level to the user's residual abilities, so that the exercises are neither too easy nor too complex. Each session, after an initial part of welcome, psychoeducation and orientation to the instrument, involves alternating virtual reality exercises, positive and corrective feedback, and suggestions of practical homework related to the cognitive function trained during the session that the individual should try during daily life.
Study NCT06579378 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: WEB-Health
Description: The intervention includes a series of 3 webinars focused on active ageing promotion. In particular, each webinar will regard topics related to healthy lifestyle, such as physical activity in old age, effective communication, stress management, technologies and health. Each webinar will be conducted by a mental health professional, and it will be delivered in real-time in a group (plenary).
Study NCT05715255 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Automated Telephone Symptom Management (ATMS) and Telephone Interpersonal Counseling (TIP-C)
Description: Participants randomized to the adaptive intervention are telephoned weekly and asked to enter by pin-pad or voice the severity of the PRO-CTCAE items on a 0-4 scale, with 0 being none and 4 being very severe. Participants are mailed the Symptom Management and Survivorship Handbook in their preferred language (English or Spanish). Survivors who rated any item at moderate or higher (2-4) will be referred by the ATSM to read the corresponding chapters in the Handbook and given a call back in 24 hours to inquire about the severity of the reported symptom, whether it has improved or worsened, and whether the participant reported it to their HCP, or the HCP has contacted the survivor. Participants that report elevated symptoms for two consecutive weeks are rerandomized to continue the ATSM alone or continue the ATSM with TIP-C added for 8 weeks. TIP-C is delivered by a masters prepared counselor with cancer expertise via weekly 30-minute phone calls using interpersonal techniques.
Study NCT05479552 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Syn-One Test
Description: CND Life Sciences is expanding the utility of its diagnostic technology, the Syn-One Test, to pathologically distinguish between early DLB and Alzheimer's disease to prevent misdiagnoses and establish the relationship between progression and α-synuclein deposition by measuring α- synuclein accumulation in patient's nerve fibers using a simple skin punch biopsy.
Study NCT05715255 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control comparator
Description: Survivors in the active control will receive weekly AVR assessments of PROCTCAE symptoms, and summary of these assessments will be sent securely to HCPs. Survivors will not receive the Handbook and will not be prompted by the AVR to contact HCPs unless the symptoms are severe.
Study NCT06238492 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: game-like computerized activities
Description: Experimental
Study NCT06238492 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: game-like computerized activities
Study NCT04981522 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Indigenously adapted problem management plus (IA-PM+)
Description: The IA-PM+ manual would be comprised of the following evidence-based techniques: (a) problem solving, (b) stress management, (c) behavioral activation and (d) accessing social support. The IA-PM+ intervention consisting of five sessions, will teach the participants techniques to manage their emotional problems.
Study NCT06585254 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous vagus nerve stimulator
Description: A device attached to the tragus of the ear which when activated stimulates an ascending branch of the vagus nerve
Study NCT05580991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAN1012
Description: CAN1012 IT injection (once every 4 weeks)
Study NCT05640999 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Vaginal brachytherapy
Description: Vaginal brachytherapy should be delivered using a vaginal cylinder, or alternatively ovoids
Study NCT05640999 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy (EBRT +/- brachytherapy)
Description: Treatment is to be delivered using 4-18 MV photons. MV, kV or CBCT imaging capabilities are required. Planning systems with capability for DICOM data transfer must be used.
Study NCT06259942 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: İntervention 1 group (underbody heater group only)
Description: Resistive heaters can be set to 38-40°C and are used together with the control unit to which they are connected. In the study, an underbody heater (MEDWARM W 300 IM 190MS branded) system measuring 1900x500x40mm was used. In this study, the underbody heater was set to 38°C for patients. Before use, a surgical drape was placed over it to prevent direct patient contact.
Study NCT06259942 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: İntervention 2 group (group using both underbody heater and heated iv liquid)
Description: IV fluids should be warmed to protect patients from unwanted hypothermia during surgery. One liter of saline solution given at room temperature decreases body temperature by 0.25˚C in adults. Therefore, the fluids given to the patient should be heated to 33 40˚C. In the guideline published by the Turkish Anesthesia Society, it is stated that if more than 1000 2000 mL of fluid is to be given to patients, it should be heated at 37°C (TARD, 2013). In this study, both IV fluids were heated between 37 and 39°C and given to the patient and heated with carbon fiber underbody heaters.
Study NCT06259942 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Group
Description: no active heating treatment was applied in this group
Study NCT05640999 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation
Description: Observation
Study NCT06267599 — intervention group
Intervention type: PROCEDURE
Intervention: ACAR-Style Bladder Suture
Description: In cases where dissection is not possible, the upper border of the bladder is opened transversely with a cutter, and the ureteral catheters and trigone inside the bladder are observed. The bladder invasion border is re-evaluated intravesically. The uterine arteries are held bilaterally with a sensitive clamp that does not crush the uterine arteries. Then, the uterus is incised from the upper border of the bladder without damaging the bladder and the predetermined myometrial invasion area is resected. After the placenta is removed, the cervical canal is found and marked with a number one vicryl suture. In these patients, the placental material is removed in pieces in the cervix area where the bladder is invaded. After the removal of the placenta, the cervix in the lower segment of the uterus is orientated and sutured together with the bladder, and this area is closed.
Study NCT05278377 — intervention group
Intervention type: BEHAVIORAL
Intervention: Apprenti en Action program
Description: The Apprenti en Action program aims to teach students how to read and follow recipes, prepare and cook various foods using various culinary techniques, and apply food safety practices. Students are also taught the basics of healthy food, nutrition, and cooking.
Study NCT06151197 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EN3835
Description: Biologic: EN3835 injection
Study NCT06151197 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo injection
Study NCT06308159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vebeglogene autotemcel
Description: Autologous HSPCs transduced with self-inactivating lentiviral vector encoding functional HBB gene and resuspended in cryopreservative solution in the final immediate container for the intended medical use.
Study NCT05317468 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contraceptive Counseling
Description: Patients will receive contraceptive counseling to review all available contraceptive methods prior to their visit with a clinician.
Study NCT06527989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 2000 mg
Description: antibiotic prophylaxis
Study NCT06243978 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: liebria
Description: Participants will receive access to the digital health intervention liebria in addition to TAU
Study NCT06243978 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: information brochure on hypertension
Description: Participants will receive an information brochure on hypertension
Study NCT06651021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: balcinrenone/dapagliflozin
Description: Each participant will receive a single dose of balcinrenone/dapagliflozin 40 mg/10 mg capsule on Day 1 under fasted condition.~Each participant will be involved in the study for up to 35 days.
Study NCT06649708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HX044
Description: Conventional dose-escalation design with 3+3 cohort size. All administered on a Q3 weekly basis. Dose escalation will be based on the absence of DLTs during the 21-day DLT evaluation after a review of safety data by the Safety Review Escalation Committee. Subjects will continue on study treatment until the subject develops an intolerable toxicity, withdraws consent, develops progression of disease, death, lost to follow-up, start of new anticancer treatment or up to study treatment duration of 24 months, whichever comes first.
Study NCT05273710 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Regular toast and juice
Description: Participants consume a single test meal composed of regular whole wheat toast and apple juice, and zinc absorption is measured.
Study NCT05273710 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: High phytate toast and juice
Description: Participants consume a single test meal composed of high phytate whole wheat toast and apple juice, and zinc absorption is measured.
Study NCT05273710 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Regular toast and juice, with folic acid
Description: Participants consume a single test meal composed of regular whole wheat toast and apple juice, with 400 mcg folic acid; and zinc absorption is measured.
Study NCT02804828 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Individualized mitochondrial cocktail
Description: Nutrient cocktail comprising: thiamine, nicotinamide, pantothenic acid, riboflavin, L-carnitine, alpha lipoic acid, CoQ10, vitamin C, vitamin E, and omega 3 fatty acids (Cod Liver Oil).
Study NCT02804828 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: 6 months for the double-blind phase
Study NCT05452538 — intervention group
Intervention type: DEVICE
Intervention: Transfusion
Description: Data from patients who were transfused at the Centre Léon Bérard from the day of surgery to the 10th postoperative day will be analyzed.
Study NCT05511285 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Cognitive Behavioural Therapy for Insomnia
Description: 6-10 weeks of digital cognitive behavioural therapy for insomnia (Sleepio) delivered online, in addition to usual care.
Study NCT04741503 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breast Cancer Screening Decision Support Tool
Description: -Provides a description of screening mammography, current screening recommendations, benefits and downsides, narratives, and questions for the participant's physician.
Study NCT04741503 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: National Cancer Institute Breast Cancer Screening PDQ
Description: -Provides current information about breast cancer screening and is meant to inform and help patients
Study NCT04849026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clozaril 100 mg (Clozapine)
Description: 2 Doses/Day for 10 days
Study NCT04849026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WID-CLZ18
Description: 2 Doses/Day for 10 days
Study NCT05684250 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auditory biofeedback training
Description: For the auditory biofeedback training, subjects are provided with two tones while fixating a target, one tone related to their accommodative response and the second to the target distance. Their task is to match these tones.
Study NCT05507554 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioid
Description: Drug: intravenous injection Tramadol 50 mg and then oral capsule Tramadol 50 mg, once patient starts taking orally.~Designated coated 14 days supply of pain medication (oral capsule Tramadol 50 mg) will be given to the patients on discharge. For Pain control oral capsule Tramadol 50 mg is administered 2 times per day until the stent will be removed in clinic 2 weeks later.
Study NCT05507554 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non-Opioid Analgesic
Description: Drug: intravenous injection Paracetamol 1 Gram and then oral Tablet Paracetamol 1 Gram, once patient starts taking orally.~Designated coated 14 days supply of pain medication (oral Tablet Paracetamol 1 Gram) will be given to the patients on discharge. For Pain control oral Paracetamol 1 Gram is administered 3 times per day until the stent will be removed in clinic 2 weeks later.
Study NCT05507554 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non-Opioid
Description: Drug: intra muscular injection Diclofenac Sodium 50 mg and then oral Tablet Diclofenac Sodium 50 mg, once patient starts taking orally.~Designated coated 14 days supply of pain medication (oral Tablet Diclofenac Sodium 50 mg) will be given to the patients on discharge. For Pain control oral Diclofenac Sodium 50 mg is administered 2 times per day until the stent will be removed in clinic 2 weeks later.
Study NCT06544213 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control Group
Description: 60 days of strict head down tilt bed rest at all time. No countermeasure program is performed.
Study NCT06544213 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Countermeasure Supine Bike
Description: 60 days of strict head down tilt bed rest at all time. The exercise starts at 40% of VO2max for 5 minutes, followed by a series of 2-minute high- and low-intensity intervals for 20 minutes. 2-minute high-intensity intervals are at 65% VO2max, 70% VO2max, 80% VO2max, 80% VO2max, 70% VO2max and 65% VO2max. 2-minute low-intensity intervals are at 40% VO2max. 3 minutes at 40% of VO2max will end the exercise.~VO2max is measured for each volunteer in supine position.